Pan-cancer mapping of transcript-driven subcellular localization switching suggests candidate mechanisms of immune evasion and immunotherapy resistance
Differential splicing has been extensively characterized at the level of individual splicing events, yet a systematic pan-cancer characterization of transcript-driven subcellular localization switching is lacking. Using matched tumour and healthy tissue samples across 14 TCGA cancer types, we predicted the subcellular localization of every protein-coding isoform and grouped transcript expression into three localization classes: transmembrane/cell surface (TM), secreted (Sec), and intracellular (Int). We defined a localization switch as a tumour-associated redistribution of transcript usage between these localization classes and identified 977 genes, corresponding to 3,723 gene-by-cancer localization-switch events, many of which recurred across multiple cancer types. Among these, we highlight representative switches with potential implications for immune regulation, intrinsic cancer-cell function, and soluble decoy formation. Together, our results establish transcript-driven subcellular localization switching as a recurrent consequence of alternative splicing in cancer and provide a framework and resource for investigating its potential roles in immune evasion, therapeutic resistance, and cancer adaptation.
Authors
- Lars Rønn Olsen (ORCID: https://orcid.org/0000-0002-6725-7850)
- Javier Herranz del Cerro
- Federico De Masi
Institutions
- University of Copenhagen (DK)
- Novo Nordisk Foundation (DK)
- LEO Foundation (DK)
Publication Details
- Journal
- Frontiers in Molecular Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fmmed.2026.1924616
- Primary Topic
- RNA Research and Splicing
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Novo Nordisk
- LEO Fondet
- HORIZON EUROPE Framework Programme